S. Tsuchiwata

Evaluation of Bayesian Estimation of Pharmacokinetic Parameters

A. Yafune, K. Mihara, H. Ogata, 2005, Therapeutic drug monitoring.

The Comparability of Etanercept Pharmacokinetics in Healthy Japanese and American Subjects

J. Korth-Bradley, S. Kawai, S. Tsuchiwata, 2006, Journal of clinical pharmacology.

Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis

T. Matsui, T. Hibi, Mamoru Watanabe, 2019, Inflammatory Intestinal Diseases.

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies

T. Nicholas, G. D'Haens, W. Sandborn, 2022, Clinical pharmacology and therapeutics.

[Population pharmacokinetic analysis of two theophylline formulations in premature neonates and infants with apnea].

K. Kushida, K. Hanada, H. Ogata, 2008, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

Safety and pharmacokinetics of bapineuzumab in a single ascending‐dose study in Japanese patients with mild to moderate Alzheimer's disease

E. Kirino, H. Baba, H. Arai, 2016, Geriatrics & gerontology international.

Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach

J. Kushner, T. Nicholas, C. Su, 2022, Clinical pharmacology in drug development.

Baseline Albumin Level Is Not a Significant Predictor of Tofacitinib Efficacy in Patients with Ulcerative Colitis: Results of Multivariate Exposure-Response Analysis

D. Rubin, A. Tinsley, G. Lichtenstein, 2018, American Journal of Gastroenterology.

Computational design of clinical trials using a combination of simulation and the genetic algorithm

Y. Tsuji, S. Tsuchiwata, 2023, CPT: pharmacometrics & systems pharmacology.